LoginSignup
immagine del profilo
Aktien Stammtisch
@Aktien_Stammtisch
2G·

CAGRISEMA DEMONSTRATES SUPERIOR WEIGHT LOSS IN ADULTS WITH OBESITY OR OVERWEIGHT IN THE REDEFINE 1 TRIAL

$NVO (-18,32%)
$LLY (+1,78%)


Achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo; CagriSema achieved a superior weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg


$LLY long on this?

3
6 Commenti
immagine del profilo
Tino@parlania
2G
whats bad about this news exactly for novo?
•
1
•
Visualizza tutti 4 ulteriori risposte
immagine del profilo
Aktien Stammtisch@Aktien_Stammtisch
2G
Notably, 40.4% of patients on CagriSema achieved ≥25% weight loss, significantly outperforming the other groups. The drug demonstrated a safe and well-tolerated profile with gastrointestinal side effects being mostly mild to moderate. Results from the REDEFINE 2 trial in type 2 diabetes patients are expected in H1 2025.
••
Partecipa alla conversazione
IscrivitiAccesso